Results 131 to 140 of about 6,942 (191)

Efficacy of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in Mozambique, 2022. [PDF]

Malar J
Nhama A, Chidimatembue A, Nhamussua L, Bassat Q, da Silva C, Nhacolo A, Arnaldo P, Salvador C, Cassy A, Candrinho B, Dimene M, Carvalho E, Saifodine A, Wate F, Mucavele H, Torres-Mendoza Y, Horton B, Plucinski M, Cistero P, Mayor A, Aide P.   +20 more
europepmc   +1 more source

Brugada syndrome precipitated by uncomplicated malaria treated with dihydroartemisinin piperaquine: a case report. [PDF]

Malar J
Amir M, Mukhtar I, Tandean P, Rahmani MZ.   +3 more
europepmc   +1 more source

Drug-Drug Interaction Between Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine During Malaria Chemoprevention in Pregnant Women. [PDF]

Clin Pharmacol Ther
Mwebaza N, Roh ME, Geng YZ, Opio L, Opira B, Marzan F, Mwima MW, Ssemukuye T, Guo K, Gingrich D, Fotaki N, Kakuru A, Kizza J, Aguti M, Adrama H, Kamya M, Dorsey G, Rosenthal PJ, Aweeka FT, Huang L.   +19 more
europepmc   +1 more source

Dihydroartemisinin-Piperaquine Combination in the Treatment of Uncomplicated Plasmodium falciparum Malaria: Update on Clinical Failures in Africa and Tools for Surveillance. [PDF]

J Clin Med
Delandre O, Pradines B, Javelle E.
europepmc   +1 more source

Defining dihydroartemisinin-piperaquine resistance pathways in the malaria parasite

A terapia combinada à base de artemisinina (ACT) é o atual tratamento de primeira linha para a malária não complicada causada por Plasmodium falciparum. Neste tratamento de 3 dias, um derivado de artemisinina altamente eficiente, mas de ação rápida, é suplementado com uma droga de ação lenta e funcionalmente distinta para eliminar os parasitas ...
openaire   +1 more source

Efficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial. [PDF]

Lancet Infect Dis
Kamya MR, Nankabirwa JI, Ebong C, Asua V, Kiggundu M, Orena S, Okitwi M, Tukwasibwe S, Agaba B, Kyabayinze D, Opigo J, Rutazana D, Binagwa B, Mugwanya E, Babirye S, Sebikaari G, Condo PM, Appiah G, Nsobya SL, Conrad MD, Rosenthal PJ, Moriarty LF, Yeka A.   +22 more
europepmc   +1 more source

Acceptability of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine plus dihydroartemisinin-piperaquine in Papua New Guinea: a qualitative study. [PDF]

Malar J
Lufele E, Pascoe S, Mengi A, Auwun A, Neuendorf N, Bolnga JW, Laman M, Rogerson SJ, Thriemer K, Unger HW.   +9 more
europepmc   +1 more source

Evaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials. [PDF]

Malar J
Ouédraogo A, Ouattara D, Ouattara SM, Diarra A, Badoum ES, Hema A, Ouédraogo AZ, Hien D, Bougouma EC, Nébié I, Bocquet V, Vaillant M, Tiono AB, Sirima SB.   +13 more
europepmc   +1 more source

Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial

, 2023
Kositz C, Marks M, Bradley J, Vasileva H, Dabira E, D'Alessandro U, Mohammed N, Achan J.   +7 more
europepmc   +1 more source

Pilot implementation of intermittent preventive treatment with dihydroartemisinin-piperaquine to prevent adverse birth outcomes in Papua, Indonesia: a mixed-method evaluation.

Lancet Prim Care
Hafidz F, Candrawati F, Hoyt J, Kenangalem E, Dodd J, Lesosky M, Laksanawati IS, Ubra R, Simatupang M, Ter Kuile FO, Worrall E, Poespoprodjo JR, Hill J.   +12 more
europepmc   +1 more source